Ottawa-Health Canada is updating the Oxford-AstraZeneca and COVISHIELD COVID-19 vaccine labels to add capillary leak syndrome as a potential side effect.
Authorities also include warnings to patients with a history of illness to avoid receiving these vaccines.
Capillary leak syndrome is a very rare and serious condition that causes fluid leakage from small blood vessels (capillaries), swelling of the arms and legs, sudden weight gain, hypotension, blood thickening, low levels of albumin. Blood protein.
Health Canada and the Public Health Agency of Canada have been monitoring this condition since it was raised as a potential safety concern by the European Medicines Agency in April.
Earlier this month, EU drug regulators said six of the 78 million doses of AstraZeneca and COVISHIELD vaccines given in Europe and the United Kingdom that developed capillary leak syndrome after receiving the AstraZeneca vaccine. Announced that it has reviewed. May 27, 2021.
As of June 11, a case of capillary leak syndrome has been reported in Canada after vaccination with AstraZeneca or the COVISHIELD COVID-19 vaccine.
Health Canada has also updated the vaccine label with information on the very rare event of blood clots associated with low levels of platelets after immunization.